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ABSTRACT
Objectives: We aimed to show how increased experience of a surgery team in fMMC repair influences maternal and 
fetal/neonatal outcomes. 
Material and methods: We compare perinatal results of fMMC repair in our Fetal Surgery Center (FSC) in cohort groups for 
the early period (2005–2011 year; previous — PFSC, n = 46) and current period (2012–2015 year; current — CFSC, n = 74) 
to results of the randomized Management of Myelomeningocele Study (MOMS, 78 patients). 
Results: The maternal morbidity due to fMMC repair was low and there was no difference comparing CFSC to PFSC and 
MOMS. The frequency of iatrogenic preterm labor (iPTL) ≤ 30 weeks of gestation decreased from 34.1% in PFSC to 23.9% 
in CFSC. Iatrogenic preterm premature rupture of membranes (iPPROM) was a common complication after fMMC repair in 
all cohorts. The total reduction rate of hindbrain hernation (HH) was similar in CFSC — 90.3% and PFSC — 82.1%. 
Conclusions: The increasing experience of our surgery team in fMMC repair majorly decreased the risk of iPTL.
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INTRODUCTION
Myelomeningocele (MMC) is a serious congenital defect 
of the central nervous system (CNS). It occurs if neurula-
tion is not completed, which physiologically should hap-
pen between the 15th and 30th day after conception. MMC 
prevalence depends on race, sex, and geographical region. 
It affects about 3–4 per 10  000 live births. In Poland the 
numbers reach 4–6 cases per 10 000 live births [1].
The risk factors for MMC occurrence are: folic acid defi-
ciency (seasonal or permanent), presence of 677C > T poly-
morphism in the methylenetetrahydrofolate reductase gene, 
hyperthermia, low economic status, antispasmodic (espe-
cially valproic acid and carbamazepinum), antihistamine, 
and sulfonamides drug intake, increased BMI [2]. 
The pathogenesis of clinical signs of MMC is unclear. Two 
theories attempt to explain how abnormal cerebrospinal 
fluid (CSF) circulation influences this distinct anomaly of 
CNS. In the ‘unified theory’ of McLone and Knepper the CSF 
leakage results in posterior fossa compression and finally in 
development of hydrocephaly (HC) [3]. Regarding Heffez 
et al. neural defects in children with MMC are associated 
with a ‘two hit theory’ [4]. The disturbance of neurulation 
in the embryo is the first hit. The second one involves the 
inflammatory effect of amniotic fluid compounds and me-
chanical destruction of the protruding spinal cord that hits 
the uterine wall [4]. 
Clinical presentation of MMC in approximately 90% of 
the cases overlaps with the Arnold-Chiari syndrome [5]. 
The main consequences in later life include lower extremity 
paresis, urinary and bowel incontinence, sexual dysfunction 
and impaired psychomotor development [6, 7]. Sense and 
motor deficiency depend on the MMC location level [6, 7]. 
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Published data concerning prenatal evolution of 
Chiari Malformation type II (CM II) show that as the 
pregnancy progresses, hindbrain hernation (HH) degree 
increases and the fourth ventricle and the venous si-
nuses are gradually being compressed [6, 7]. This leads to 
inappropriate CSF circulation and progression of HC [2]. 
In more than 80% of children with CM II, the presence 
of HC in the postnatal period may entail the necessity 
of ventriculo-peritoneal shunt (VPS) implantation or en-
doscopic third ventriculostomy (ETV) [8]. In almost 50% 
of patients, the drainage system must be replaced in 
their first year of life due to its frequent obstruction and 
infection [9]. 
In further development of children with CM II, in the 
event brain stem dysfunction is present; the mortality 
reaches 35% during their first year of life [5].
The idea of in utero MMC repair that arises from the 
two ‘hit theory’ proposed by Heffez is confirmed in early 
pathomorphological studies as well as in experimental 
animal research [10]. The fMMC repair aims to protect the 
nerve fibres from the neurotoxic reaction caused by amni-
otic fluid compounds and to restore normal CSF circulation 
[11]. The fMMC repair procedure counteracts the serious 
consequences of natural in utero evolution of CM II. The 
results of a randomized trial of prenatal versus postnatal 
repair of myelomeningocele publised in 2011 clearly sho-
wed that prenatal surgery for myelomeningocele reduced 
the need for shunting and improved motor outcomes at 
30 months [5]. 
Objectives
We aimed to show how the increasing experience of our 
surgery team in fMMC repair majorly decreased the risk of 
iatrogenic preterm labor.
MATERIAL AND METHODS
Perinatal results of fMMC repair in the following cohort 
groups were compared: 
 Ū Previous study in our Fetal Surgery Center (FSC), from 
January 2005 to December 2011 (PFSC, n = 46), [12] vs
 Ū Current study in our FSC, from January 2012 to Decem-
ber 2015 (CFSC, n = 74), vs
 Ū Management of Myelomeningocele Study (MOMS), from 
February 2003 through December 2010 (n = 78), [5]. 
Patients qualification in Polish FSC, Bytom
The procedure of fMMC repair has been performed in 
the FSC of the Clinical Department of Obstetrics, Gynecol-
ogy, and Oncological Gynecology in Bytom, Poland since 
2005 [13]. Seventy-four (74) of 183 patients with CM II re-
ferred to our FSC were qualified for fMMC repair, based on 
the protocol of the randomized MOMS criteria [5].
Major inclusion criteria were: maternal age ≥ 18 years, 
single pregnancy, gestational age between 19 weeks, 0 days 
and 25 weeks, 6 days, location of fMMC at the S1 level or 
above with presence of Chiari II malformation in prenatal US 
and MRI, lateral ventricular size of fMMC less than 17 mm, 
maintain lower extremities motor function, no other major 
anomalies, normal karyotype, normal feto-placental func-
tion and consent of the parents [5].
Major exclusion criteria were kyphosis > 30°, oligohy-
dramnion, placenta previa, high risk of preterm labor (short 
cervix ≤ 20 mm, previous preterm labours), previous hyster-
otomies, contraindication for epidural analgesia, maternal 
diseases like diabetes mellitus type 1, hypertension, obesity 
(BMI > 35), thrombophilia, and infectious diseases (TORCH, 
abnormal bacterial flora in the cervical canal, respiratory 
tract infection, urinary tract infection, chronical infectious 
diseases of urinary tract) [13–15].
Like in other medical centers for maternal and fetal 
surgery, the decision of fMMC repair taken by the prospec-
tive parents was autonomous. The information about the 
fMMC repair procedure, the influence of CM II on child’s 
further development and quality of life was presented by 
the perinatal team. 
The primary end points were maternal morbidity, pre-
term labor (iPTL) ≤ 30 weeks of gestation, iatrogenic pre-
term premature rupture of membranes (iPPROM), reduc-
tion of hindbrain herniation, severe infections < 7 days of 
life. In order to objectively evaluate the posterior fossa, 
abnormality, based on MRI, grading was assigned as fol-
lows: grade 0, normal;  grade 1, visible fourth ventricle 
and cisterna magna without cerebellar displacement be-
low the foramen magnum, tentorium could be vertically 
oriented, and tectal breaking could be present; grade 2, 
visible cisterna magna without displacement of the cer-
ebellum below the tentorium, no visible fourth ventri-
cle; and grade 3, displacement of cerebellum below the 
foramen magnum and obliteration of all posterior fossa 
CSF spaces.
Grading was assigned by the attending neuroradiologist 
(L.T.B.). It was not possible to do this in a blinded manner, 
since the approximate age of the fetus and the preoperative 
or postoperative status was apparent from the MRI studies. 
The evaluation of postoperative evolution of cerebral 
changes of HH and ventriculomegaly (VM) was based on 
MRI, performed in 30+4–33+0 gestational weeks in the group 
PFSC — 28/44 and CFSC — 31/71 (Fig. 1). 
In addition, serial US examinations every 7–10 days 
after fMMC repair were performed to verify CM II evolution, 
with measurement of the anterior diameter (AD) of VM, HH 
degree, and fetal well-being. 
Diagnosed HH degree was defined based on the Sutton 
et al. [16] scale. 
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VM was diagnosed when the atria of the lateral cerebral 
ventricles measure > 10 mm in diameter on an axial view 
of the fetal head, obtained at the level of the thalami [17]. 
The severity of VM was classified as: mild (lateral ventricu-
lar diameter between 10–12 mm), moderate (lateral ven-
tricular diameter between 12.1–15 mm), and severe (fetal 
VM > 15 mm), sometimes also classified as fetal hydro-
cephaly (lateral ventricular diameter > 95 pc) [18]. 
Statistical analysis
The analysis was performed using MedCalc 14.12.0 (Med-
Calc Software bvba, Ostend, Belgium). Values were present-
ed as percentages and mean values ± SD and ranges. The 
comparison of qualitative variables with data in published 
cohorts was done with χ2 or χ2 for trend tests. The difference 
was considered statistically significant when, the ‘p’ value 
was below 0.05.
fMMC repair — surgical protocol
Twenty-four hours before the fMMC repair procedure, 
Betamethasone 24 mg (as RDS prevention) Ceftazidime 
2.0 g i.v (antibiotic prophylaxis), Indomethacin 150 mg/24 h, 
and Nifedipine 40 mg/24 h (tocolytic treatment) were ad-
ministered. 
The surgery was conducted under simultaneous gen-
eral anesthesia and subdural analgesia. The abdomen was 
opened with the Pfannenstiel incision or in the scar after 
previous laparotomy. The incision of the uterine muscle was 
made in the mid sagittal line above the MMC, ≥ 5 cm from 
the placenta margin. The amniotic fluid was then extracted 
and the incision was enlarged using Auto Suture Poly CS™ 
stapler (Covidien Mansfield, MA, US). The fMMC was manu-
ally placed into the hysterotomy site. For fetal anesthesia, 
opioids (fentanyl 10–20 mcg/kg) and muscle a relaxant drug 
(Pancuronium 0.1–0.3 mg/kg) were administered. 
There are essentially no differences between prenatal 
and postnatal procedures performed by the pediatric sur-
geons during MMC repair. Waterproof closing of the dura is 
usually very difficult due to the tissue fragility. In our opinion 
the most important part of MMC closing is placode and 
cauda equine release. The next step is mobilization of the 
fascio-muscular layers from the both sides (erector spinalis 
muscles) to the median line applying single sutures. Sutur-
ing of the skin caused minor difficulties but, when it is neces-
sary, relaxing incisions, or slight cutaneous flap movements, 
were performed. The fetal part of the surgery on average 
takes 30–40 min but up to 60 min in very difficult cases.
The amniotic fluid was supplemented with warm crys-
talloid fluids. The closure of the uterine muscle with two 
layers of monofilament continuous suture was preceded by 
intra-amniotic infusion of 1.0 g Ceftazidime. Figure 2 pre-
sents the fMMC repair steps.
Figure 1. A. Fetal MRI, SSFSET2 sequence, sagittal plane: Chiari II — descent of the posterior fossa structures into cervical vertebral canal, small 
posterior fossa, supratentorial hydrocephalus, spin bifida cum myelomeningocele (arrows); B. Fetal MRI, SSFSET2 sequence, axial plane: Chiari 
II — spina bifida, myelomeningocele (arrows); C. Fetal MRI, SSFSET2 sequence, coronal plane: Chiari II — descent of the posterior fossa structures 
into cervical vertebral canal, small posterior fossa, supratentorial hydrocephalus (arrows)
Figure 2. The stages of fMMC repair (A — hysterotomy,  
B — stabilization of fetus with exposed MMC, a —uterus, b — fetus 
back, c — MMC sack, C — closed MMC, D — closed uterus); MMC 
— myelomeningocele
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Magnesium sulfate 2 g i.v was administered when open-
ing and closing the uterine muscle. The hemodynamic con-
dition of the fetus was monitored by Doppler ultrasound by 
analyzing FHR and PI indices of the umbilical artery.
After the operation, all women were monitored for signs 
of intrauterine infection such as: increased basal body tem-
perature, maternal heart rate, fetal heart rate, C-reactive pro-
tein, and procalcitonin. Antibiotic prophylaxis was contin-
ued until postoperative day 7 with Ceftazidime 2.0 g/24 h i.v. 
Analgesic treatment included Marcaine through an epidural 
catheter < 7 days. Tocolytic treatment included Nifedipine 
20 mg/24 h p.o. and Fenoterol Hydrobromide 20 mg/24 h 
p.o. The information concerning postoperative manage-
ment was discussed in detail in our previous study and 
MOMS study [5, 12]. 
In the fMMC repair group an elective cesarean section 
was performed at 37 weeks of gestation, or earlier if the 
complications threatened maternal or fetal life. The condi-
tion of the uterine scar after hysterotomy was assessed 
during the cesarean section. 
RESULTS
Data of the study population is presented in Table 1. Our 
study group consisted of 74 patients, but because of three 
fetal death [1 intraoperation fetal death (IUFD) and 2 within 
24 hours after fMMC repair (NND)] in the final analysis we 
took into consideration 71 neonates, except for mortality rate. 
Range of gestational age at the time of fetal surgery 
for MMC was defined as 19+0–25+6, according to inclusion 
criteria. In our study fMMC repair performed between 22+3– 
–25+6 weeks of gestation. Nearly half of the patients were op-
erated in 23+6 weeks of gestation. Five (6.8%) patients with 
low fMMC location < S1 were exposed to early MRI between 
19+2–21+3 weeks of gestation and CM II was diagnosed only 
in a single case. Among the remaining 4 patients, MRI was 
repeated in 25 weeks and late HH and VM which qualified 
for fMMC repair were diagnosed.
The maternal morbidity after fMMC repair encompasses 
typical complications for surgical operations during preg-
nancy. Pre-edematous state of pulmonary edema as well as 
peritonitis was observed only in 1 patient in both current 
and previous study (accordingly 1.4% vs 2.2%). The need of 
blood transfusion occured in 4 (5.4%) patients in CFSC group 
and in 3 (6.5%) patients in PFSC group. Comparing CFSC 
to MOMS and PFSC, the frequency of complications which 
could cause serious consequences (pre-edematous state 
without secondary intubation and ICU treatment, blood loss 
and peritonitis) were low and comparable (Tab. 2).
The analysis of perinatal results after fMMC repair in 
CFSC group showed following complications: iatrogenic 
oligohydramnion 12/71 (16.9%), chorioamniotic membrane 
separation (CMS) 11/71 (15.5%) and was insignificant com-
pared to MOMS and our previous study PFSC, respectively: 
16 (21), 20 (26) vs 4 (8.7%), 8 (17.3%). iPPROM was the most 
frequent iatrogenic complication after fMMC repair and 
its frequency in CFSC was 31/71 (43.6%) of similarly high 
frequency of iPPROM noted in MOMS 36/78 (46.2%) and 
in our study from the previous period PFSC 24/46 (52.2%). 
Despite the positive trend, the comparison of the results 
of all cohorts does not achieve statistical significance. 
iPTL ≤ 30 weeks of gestation which is a serious consequence 
of iPPROM occurred in 17/71 (23.9%) patients in our centre 
where as in 10/78 (12.8%) in Adzick’s study. Comparing 
this value with PFSC 15/44 (34.1%) is not significant. Site 
evaluation during cesarean section points to a completely 
healed, hysterotomy site, in the CFSC cohort 63/71 (88.7%) 
vs MOMS 49/76 (64.5%), p < 0.001. In two patients in CFSC 
and PFSC (accordingly 4,1 % and 6,5%) during cesarean sec-
tion we observed complete dehiscence of hysterotomy site 
which needed surgical repair. It was the only complication 
which we reported during cesarean section in our patients. 
Our data indicates that 17/71 (23.9%) of children were 
born in ≥ 37 weeks of gestation and it was similar in MOMS 
study. The result of labour ≥ 37 weeks improved compared 
to our last observation (PFSC) where this value was lower 
8/44 (18.2%) vs MOMS 16/78 (20.5%), p < 0.05.
Fetal results 
HH improvement despite greater number of phenom-
enon, did not achieve statistical significance in compar-
ing CFSC vs PFSC, respectively for degree: partial ≥ 1° 
15/31 (48.4%) vs 13/28 (46.4%), complete 13/31 (41.9%) 
vs 10/28 (35.7%) and any 28/31 (90.3%) vs 23/28 (82.1%). 
Table 1. The results of qualification for fMMC repair among CM II 
patients treated in FSC Bytom (n = 74)
Gestational age at IUMR based on last 
menstrual period and ultrasound in 11–
14 weeks of gestation; mean (range)
23+6 ± (22+3–25+6)
Normal feto-placental function; n (%) 74 (100)
Lower extremities motor function/feet 
deformity; n (%) 53 (71.6)
Increased lateral ventricles width anterior 
diameter; n (%) 61 (82.4)
fMMC level; n (%)
 ≥ Th12 0
 L1–S1 66 (89.2)
 < S1 5 (6.8)
Degree of hindbrain herniation; n (%)
 0 — absent 0
 I — low 7 (9.5)
 II — moderate 64 (86.5)
 III — severe 0
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Only in two fetuses with CM II, in both cohorts, was observed 
HH progression ≥ 1° and in 6 cases HH degree after fMMC 
repair did not change. 
We compared the width of the lateral ventricle before 
and after IUMR measuring AD in degree: mild (10–12 mm) 
or moderate (12.1–15 mm). It was observed significant 
inhibition of VM development in CFSC vs PFSC respectively: 
25/31 (80.6%) vs 15/28 (53.6%), p < 0.05. The comparison 
of width of the lateral ventricle in MRI during qualification 
and after fMMC repair (in 30+4–33+0 gestational week) point 
to VM inhibition in the groups CFSC vs PSC in the following 
way: 25/31 (80.6%) vs 15/28 (53.6%), p < 0.05. We did not 
achieved improvement relative to frequency of progressive 
VM/HC > 95% comparing our cohorts. In 5 (17.8%) fetuses 
with MMC localization < S1, VM was not still observed after 
fMMC repair.
Neonatal results 
In infants born prematurely, advanced neonatal proce-
dures as nCPAP ventilation support 24/71 (33.8%) and me-
chanical ventilation 19/71 (26.7%) were applied. Comparing 
CFSC vs MOMS, ventilation support for respiratory distress 
syndrome was required 43/71 (60.6%) vs 16/77 (21%) infants, 
p < 0.001. Concerning the neonatal outcome the cumulative 
mortality stands at 4/74 (5.4%) in our centre. 
Unexpected, intracranial haemorrhage (IH) I0–II0 was ob-
served in a statistically significant frequently in CFSC vs PFSC 
following: 34/71 (47.9%) vs 4/44 (9.1%), p < 0.001. However, 
IVH I0 without clinical syndromes were observed using ultra-
sound examination in near half of cases in the CFSC group 
34/71 (47.9%). A high percentage was observed of neonatal 
infections diagnosed < 7 day of life: CFSC 25/71 (35.2%) and 
PFSC 12/24 (50%), which could be attributed to the need 
for invasive neonatal procedures. Despite the improvement 
of these results, the difference is statistically insignificant. 
The frequency of a serious complication, sepsis in our co-
horts, CFSC 5/71 (7.0%) and PFSC 2/24 (8.3%) was low and 
is comparable with those reported in MOMS 4/77 (5.2%). 
The final effect of changes in the CNS structures in 
the form of decreasing HH was observed in our study in 
28/31 (90.3%) of fetuses with CM II whereas non-progressive 
VM diagnosed in ultrasonography examination before cesar-
ean section concerned 25/31 (80.6%) of fetuses with fMMC. 
DISCUSSION
Up until 1997, only postnatal treatment served as a ther-
apeutic option that eased the consequences of in uterine 
damage of the nervous system in fetuses with CM II. The first 
fMMC repair in the US (CHOP and VUMC) has brought surgi-
cal procedures to Europe and beyond. The results of these 









Maternal results n (%) 
Pre-edematous state of pulmonary edema without secondary intubation and 
intensive care unit treatment 1 (1.4) 5 (6.4) 1 (2.2)
Preeclampsia/Hypertension 3 (4.1) 3 (3.8) 2 (4.3)
Gestational diabetes mellitus 2 (2.7) 4 (5.1) 1 (2.2)
Blood transfusion 4 (5.4) 7 (9.0) 3 (6.5)
Peritonitis 1 (1.4) 2 (2.6) 1 (2.2)
Amniotic membranes and amniotic fluid n (%)
Chorioamniotic membrane separation (CMS) 11/71 (15.5) 20 (25.6) 8 (17.3)
iatrogenic oligohydramnios AFI < 5cm, > 21 days 12/71 (16.9) 16 (20.5) 4 (8.7)
iPPROM syndrome 31/71 (43.6) 36 (46.2) 24 (52.2)
Chorioamnionitis 3/71 (4.2) 2 (2.6) 2 (4.3)
Preterm placental abruption 2/71 (2.8) 5 (6.4) 2 (4.3)
Hysterotomy site (evaluation during cesarean section) n (%)
Completely healed  63/71 (88.7)### 49/76 (64.5) 34 (73.9)
Partial dehiscence 4/71 (5.6) 7/76 (9.2) 3 (6.5)
Complete dehiscence 2/71 (2.8) 1/76 (1.3) 2 (4.3)
Fetal extrusion into peritoneal cavity (complete uterine rupture with intact 
membranes and placenta) 1/71 (1.4) 0 1 (2.2)
###p < 0.001
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studies were reported as short term observational studies 
of cohort groups. The comparison of qualification criteria 
and surgical protocols remain unanimous [5, 12, 14, 19]. 
Whereas long-term observation of childhood develop-
ment after fMMC repair was assessed only in the CHOP 
study [20, 21].
The maternal morbidity after fMMC repair is typical 
surgical complications such as blood loss and peritonitis 
(Tab. 2). Gollombeck et al. [22] in 2006, noted that the most 
common complications after maternal-fetal surgery was 
a higher incidence of lung edema and respiratory insuf-
ficiency (27.6%), re-intubation (2.3%), and intensive care 
treatment. The MOMS study and our own experiences, as 
well as the recent VUMC study, have shown that maternal 
safety increased significantly [5, 12, 23], in contrast with 
previous data from Moldenhauer et al. [24] In post-MOMS 
analysis at the Children’s Hospital of Philadelphia, showed 
lower complication rates than in the actual trial, including 
pulmonary oedema 2/100 (2%). Furthermore, in our cohorts, 
the results of maternal morbidity show lower health risk dur-
ing the intraoperative period. Al-Refai et al. [25], analyzing 
maternal morbidity associated with various perinatal inva-
sive procedures, concluded that adverse maternal effects 
are probably rare, when done in an expert center. 
Moreover, using  atosiban  instead of  magnesium sul-
fate in the context of open fetal surgery may significantly 
improve the maternal safety [26]. 
Perinatal iatrogenic complications of the uterine-placen-
tal-fetal unit are the main limitation of fMMC rehabilitation 
and they result from the invasive surgical procedure and 
pharmacological treatment [15]. Pulmonary oedema is the 
main iatrogenic complications for mother and it results from 
the use of high doses of magnesium sulfate. Whereas the use 
of COX-1 and COX-2 inhibitors can lead to oligohydramnions 
which results from the inhibition of fetal urine production.
In the current studies, iatrogenic iPPROM, iatrogenic 
oligohydramnion, and CMS were reported in 31/71 (43.6%), 
12/71 (16.9%) and 11/71 (15.5%) cases, respectively. Unfor-
tunately, these values remain comparable. CFSC vs PFSC, and 
insignificant compared to the MOMS results [5]. In the Soni 
et al. [27] study, frequency of CMS was 21/88 (23.9%) and 
iPPROM occurred in 27/88 (30.7%) of cases after fMMC re-
pair. In this study, local or global CMS, which was diagnosed 
by ultrasound, was significantly associated with iPPROM 
(59.1 vs 21.2%, p = 0.008) and earlier gestational age at 
delivery (32.1 ± 4.2 vs 34.4 ± 3.5 weeks, p = 0.01).
In our study, iatrogenic preterm labor, ≤ 30 weeks of 
gestation, occurred in 17/71 (24) cases as a consequence 
of iPPROM. 17 (24%) children were born in ≥ 37 weeks of 
gestation. Many of the unfavorable perinatal outcomes 
were demonstrated as early experiences of our FSC. In more 
recent observations the perinatal outcomes have improved 
as the result of learning curve [15]. It is worth to emphasis 
that the learning curve has certainly the influence in the re-
duction of perinatal complication but after achieving some 
ability, the rate of complications remain on the stable level.
The main results concerning neonates are caused by 
complications after fMMC repair. In our current study, one 
fetal death and one miscarriage in 22+3 occurred during 
fMMC repair before uterine muscle closure. Three pregnan-
cies lost in 24+2, 25+2 and 24+4 weeks occurred up to 48 hours 
after IUMR due to severe CMS, iPPROM, and placental abrup-
tion. In comparison to other researchers, the cumulative 
postnatal mortality is of acceptable value and much like 
the MOMS study results and other reports [5, 12, 15]. The 
total frequency of prematurity ≤ 30 weeks in comparison 
of our cohorts was the following: CFSC 17/71 (23.9%) vs 
PFSC 15/44 (34.1%) and it is notably, but not significantly 
lower. Prematurity contributed to an increase necessity to 
apply ventilation support for RDS in the following: CFSC 
43/71 (60.6%) vs MOMS 16/77 (20.8%) p < 0.001 [5]. 
It is necessary to emphasize that not only prematurity 
caused by fMMC repair, but also CM II neurological dys-
functions are the independent risk factors for increased 
intensive neonatal care procedures, even among newborns 
born at term. Da Silva et al. reported that in 97 newborns 
delivered ≥ 37 weeks of gestation with untreated CM II, 
the neurological dysfunction were the reason for nCPAP 
ventilation in 29/97 (29.9%) (OR 4.55, 95%, CI 1.82–11.41) 
and newborn intubation in 13/97 (13.4%) (OR 3.94%, 
CI 1.14–13.59) [28]. At one minute after birth 24 newborns 
were scored < 7 Apgar points (OR 95%, CI 0.99–7.57) [28]. 
The main aim of fMMC repair is the neuroprotection of 
exposed spinal cord nerve fibres from toxic effect of amni-
otic fluid and secondarily to restrict the evolution of CM II 
cerebral changes in the form of VM and HH [29]. 
The evaluation of the brain in magnetic resonance imag-
ing in 30+4–33+0 gestational week points to a high percent-
age of improvement in hindbrain herniation in our cohorts: 
CFSC 28/31 (90.3%) and PFSC 23/28 (82.1%). Additionally, 
we obtained significant improvement into fetal conditions 
in the form of non-progressive VM: CFSC 25/31 (80.6%) vs 
15/28 (53.6%), p < 0.05. 
The evolution of changes in the CNS observed after 
fMMC repair can prove to restore a normal CSF circula-
tion. Danzer et al. [30] demonstrated that as the pregnancy 
progressed the lateral ventricular width did not increase in 
22 fetuses after fMMC repair, contrary to the fetuses with 
CM II treated postnatally. In our previous study we observed 
stationary VM with ventricular width not exceeding the di-
ameter measured at the time of surgical qualification in 53% 
cases after fMMC repair and in 13% cases without treatment 
(CI 4.01, 1.05–15.3, p = 0.04) [12]. Decreased VM incidence in 
children that underwent fMMC repair is associated with the 
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Table 3. A comparison of fetal condition and evolution of CM II and neonatal results after fMMC repair
CFSC n = 74 MOMS Adzick 2011[5] n = 78 PFSC Zamłyński 2014 [12] n = 46
Mortality, n (%)
 Intrauterine foetal death (IUFD) 1/74 (1.4) 0 0
 Neonatal death (NND) < 7 days 3/74 (4.1) 2 (2.6) 2 (4.3)
 Cumulative 4/74 (5.4) 2 (2.6) 2 (4.3)
Gestational age at delivery, n (%)
 ≤ 30 weeks 17/71 (23.9) 10 (12.8) 15/44 (34.1)
 31–33 weeks 16/71 (22.5) 26 (33.3) 11/44 (25)
 34–36 weeks 24/71 (33.8) 26 (33.3) 10/44 (22.7)
 ≥ 37 weeks 17/71 (23.9) 16 (20.5) 8/44 (18.2)
p < 0.05 vs PFSC for trend
Evaluation of the brain in magnetic resonance imaging (30+4–33+0 gestational week)
Hindbrain herniation improvement, n (%)
 Partial ≥ 1° 15/31 (48.4) n.a. 13/28 (46.4)
 Complete 13/31 (41.9) 10/28 (35.7)
 Any X 28/31 (90.3) 23/28 (82.1)
Hindbrain herniation progression, n (%)
 Moderate ≥ 1° 1/31 (3.2) n.a. 1/28 (3.6)
 Severe ≥ 2°X 0 0
Lateral ventricles width, n (%) 
 Non-progressive VM* 25/31 (80.6)^ n.a. 15/28 (53.6)
 Progressive VM/HC > 95%** 6/31 (19.3) 8/28 (28.6)
Neonatal weight, n (%)
 < 3 percentile 3/71 (4.2) 0 1/44 (4.2)
 < 10 percentile 12/71 (17)# 3 (3.8) 5/44 (20.8)
Fifth minute Apgar score, n (%)
 0–3  6/71 (8.4) n.a. 3/44 (16.7)
 4–7 28/71 (39.4) 8/44 (29.2)
 8–10 37/71 (52.1) 13/28 (54.2)
Ventilation support for respiratory distress syndrome (RDS), n (%)
nCPAP 24/71 (33.8) n.a. 11/44 (25.0)
Mechanical ventilation 19/71 (26.7) 12/44 (27.3)
Any support 43/71 (60.6)### 16/77 (20.8) 23/44 (52.7)
Intracranial haemorrhage (IH), n (%)
 I–II grade 34/71 (47.9)^^^ n.a. 4/44 (9.1)
 III–IV grade 2/71 (2.8) 1/44 ( 2.3)
 Any IH 36/71 (50.7)^^^ 5/44 (11.4)
Infections < 7 days, n (%)
Sepsis*** 5/71 (7.0) 4/77 (5.2) 2/24 (8.3)
Other neonatal infection 20/71 (28.1) n.a. 10/24 (41.7)
Any infection 25/71 (35.2) 12/24 (50.0)
MMC wound dehiscence, n (%) 14/71 (19.7) 10/77 (13.0) n.a.
Foot deformity, n (%) 32/71 (45.1) 39/77 (50.6) 11/44 (45.8)
^ p < 0.05; ^^^ p < 0.001 vs PFSC; #p < 0.05; ###p < 0.001 vs MOMS; X — HH improvement was defined as: partial- reduction of HH degree about 1° (from 2° to 1° HH); 
complete — redaction of HH degree from 2° to 0° or 1° to 0°; * Non-progressive VM — was defined as the some VM class before and after fMMc repair (mild fetal 
ventriculomegaly: lateral ventricular AD between 10–12 mm or moderate fetal VM: AD 12.1–15 mm); ** Progressive VM/HC > 95% was defined as increased VM class 
to severe fetal ventriculomegaly also sometimes classified as fetal HC (head circumference > 95% in given gestational age) lateral ventricular AD > 15 mm; *** Sepsis 
was defined as confirmation on blood culture G (–), G (+) at 7 days
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It should presumed that an increasing level of medical ac-
ceptance of prenatal therapy and the ability to provide non- 
directive information for parents of CM II children contribute 
to an increasing frequency and number of IUMR-centres 
in Europe.
CONCLUSIONS
FMMC repair is an invasive procedure; however, the level 
of maternal-fetal surgery safety is quite high. Comparison of 
fetal condition and neonatal results after fMMC repair: CFSC 
vs MOMS vs PFSC, points to good effectiveness in reduction 
of hindbrain herniation (HH) and reduction or prevention 
ventriculomegaly (VM). The learning curve is positive, mostly 
decreasing the risk of iatrogenic preterm labor.
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